European Journal of Heart Failure (2016) **18**, 727
doi:10.1002/ejhf.591

ERRATUM

Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489]

Stefan D. Anker[1], Stefan Schroeder[2], Dan Atar[3], Jeroen J. Bax[4], Claudio Ceconi[5], Martin R. Cowie[6], Adam Crisp[7], Fabienne Dominjon[8], Ian Ford[9], Hossein-Ardeschir Ghofrani[10,11,12], Savion Gropper[13], Gerhard Hindricks[14], Mark A. Hlatky[15], Richard Holcomb[16], Narimon Honarpour[17], J. Wouter Jukema[4], Albert M. Kim[18], Michael Kunz[2], Martin Lefkowitz[19], Chantal Le Floch[8], Ulf Landmesser[20], Theresa A. McDonagh[21], John J. McMurray[22], Bela Merkely[23], Milton Packer[24], Krishna Prasad[25], James Revkin[18], Giuseppe M.C. Rosano[26,27], Ransi Somaratne[17], Wendy Gattis Stough[28], Adriaan A. Voors[29], and Frank Ruschitzka[30]

[1]Innovative Clinical Trials, Department of Cardiology & Pneumology, University Medical Center Göttingen (UMG), Germany; [2]Bayer Pharma AG, Berlin, Germany; [3]Department of Cardiology B, Oslo University Hospital Ulleval and University of Oslo, Norway; [4]Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; [5]Unit of Cardiology, Hospital of Desenzano del Garda, Desenzano del Garda, Italy; [6]National Heart and Lung Institute, Imperial College London, London, UK; [7]GlaxoSmithKline, Middlesex, UK; [8]Servier International, Paris, France; [9]Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; [10]University of Giessen and Marburg Lung Center, UGMLC [member of the German Center for Lung Research (DZL)], Giessen, Germany; [11]Kerckhoff-Klinik Bad Nauheim, Germany; [12]Imperial College London, UK; [13]Boehringer-Ingelheim GmBH & Co. KG, Ingelheim, Germany; [14]Department of Electrophysiology, Heart Center, University of Leipzig, Leipzig, Germany; [15]Stanford University School of Medicine, Stanford, CA, USA; [16]Independent Biostatistician, Minneapolis, MN, USA; [17]Amgen, Inc., Thousand Oaks, CA, USA; [18]Pfizer, Inc., Cambridge, MA, USA; [19]Novartis Pharmaceuticals, East Hanover, NJ, USA; [20]Department of Cardiology, Charité Universitätsmedizin Berlin, Berlin, Germany; [21]King's College Hospital, London, UK; [22]BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; [23]Semmelweis University Heart and Vascular Center, Budapest, Hungary; [24]Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA; [25]United Kingdom Medicines and Healthcare Products Regulatory Agency, London, UK; [26]IRCCS San Raffaele Hospital Roma, Rome, Italy; [27]Cardiovascular and Cell Sciences Institute, St. George's University of London, London, UK; [28]Campbell University College of Pharmacy and Health Sciences, NC, USA; [29]University of Groningen, Groningen, The Netherlands; and [30]Department of Cardiology, Heart Failure Clinic and Transplantation, University Heart Center Zurich, Zurich, Switzerland

The publisher regrets that in the review article, Prof. Stefan D. Anker and Prof. Stefan Schroeder's affiliation were incorrectly published. The corrected version can be found above.

Apologies for any inconvenience caused.

© 2016 The Authors
European Journal of Heart Failure © 2016 European Society of Cardiology